D.E. Shaw & Co
XGN icon

D.E. Shaw & Co’s Exagen XGN Stock Holding History

D.E. Shaw & Co’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
34,569
+2,990
+9% +$11.6K ﹤0.01% 4284
2025
Q4 		$192K Buy
+31,579
New +$287K ﹤0.01% 4340

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

D.E. Shaw & Co's XGN Position: Q1 2026 in Review

D.E. Shaw & Co increased its Exagen (XGN) stake by 9.5% in Q1 2026, buying an estimated $11.6K and bringing the position to 34,569 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4284.

D.E. Shaw & Co first reported a position in XGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $192K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • D.E. Shaw & Co held 34,569 shares of Exagen worth $104K as of Q1 2026.
  • D.E. Shaw & Co bought 2,990 Exagen shares in Q1 2026, an estimated $11.6K.
  • Exagen made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4284 holding.
  • D.E. Shaw & Co first reported a position in Exagen in Q4 2025 and has held it in 2 quarters since.
  • D.E. Shaw & Co's Exagen position peaked at $192K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.